Hashimoto’s Encephalopathy Presenting with Progressive Cerebellar Ataxia

References

1. ↵
   1. Kirshner HS

   (2014) Hashimoto’s encephalopathy: a brief review. Curr Neurol Neurosci Rep 14, 476.
2. ↵
   1. Olmez I,
   2. Moses H,
   3. Sriram S,
   4. Kirshner H,
   5. Lagrange AH,
   6. Pawate S

   (2013) Diagnostic and therapeutic aspects of Hashimoto’s encephalopathy. J Neurol Sci 331, 67–71.
3. ↵
   1. Álvarez bravo G,
   2. Yusta izquierdo A,
   3. Carvalho monteiro G,
   4. Sánchez I

   (2017) Cerebellopathy secondary to anti-peroxidase antibody-mediated toxicity. A special case of Hashimoto encephalopathy. J Neuroimmunol 312, 1–3.
4. ↵
   1. Wood-allum CA,
   2. Shaw PJ

   (2014) Thyroid disease and the nervous system. Handb Clin Neurol 120, 703–735.
5. ↵
   1. Josephson SA,
   2. Aminoff MJ

   Neurological Complications of Systemic Disease: Adults. In: Daroff RB, Jankovic J, Mazziotta JC, Pomeroy SL, editors. 7th ed. London (UK), Elsevier, 2016, 1380, 1421. Bradley’s Neurology in Clinical Practice.
6. ↵
   1. Laurent C,
   2. Capron J,
   3. Quillerou B,
   4. Thomas G,
   5. Alamowitch S,
   6. Fain O,
   7. et al.

   (2016) Steroid-responsive encephalopathy associated with autoimmune thyroiditis (SREAT): Characteristics, treatment and outcome in 251 cases from the literature. Autoimmun Rev 15, 1129–1133.
7. ↵
   1. Brain L,
   2. Jellinek EH,
   3. Ball K

   (1966) Hashimoto’s disease and encephalopathy. Lancet 2, 512–514.
8. ↵
   1. Castillo P,
   2. Woodruff B,
   3. Caselli R,
   4. Vernino S,
   5. Lucchinetti C,
   6. Swanson J,
   7. et al.

   (2006) Steroid-responsive encephalopathy associated with autoimmune thyroiditis. Arch Neurol 63, 197–202.
9. ↵
   1. Carvalho DP,
   2. Dupuy C

   (2017) Thyroid hormone biosynthesis and release. Mol Cell Endocrinol 458, 6–15.
10. ↵
    1. Doggui R

    (2018) Immunoanalytical profile of thyroglobulin antibodies. Ann Biol Clin (Paris) 76, 695–704.
11. ↵
    1. Pyzik A,
    2. Grywalska E,
    3. Matyjaszek-matuszek B,
    4. Roliński J

    (2015) Immune disorders in Hashimoto’s thyroiditis: what do we know so far? J Immunol Res 2015, 979167.
12. ↵
    1. Blanchin S,
    2. Coffin C,
    3. Viader F,
    4. Ruf J,
    5. Carayon P,
    6. Potier F,
    7. et al.

    (2007) Anti-thyroperoxidase antibodies from patients with Hashimoto’s encephalopathy bind to cerebellar astrocytes. J Neuroimmunol 192, 13–20.
13. ↵
    1. Goodman AD,
    2. Brown TR,
    3. Krupp LB,
    4. Schapiro RT,
    5. Schwid SR,
    6. Cohen R,
    7. et al.

    (2009) Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet 373, 732–738.
14. ↵
    1. Goodman AD,
    2. Brown TR,
    3. Edwards KR,
    4. Krupp LB,
    5. Schapiro RT,
    6. Cohen R,
    7. et al.

    (2010) A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Ann Neurol 68, 494–502.
15. ↵
    1. Ilg W,
    2. Bastian AJ,
    3. Boesch S,
    4. Burciu RG,
    5. Celnik P,
    6. Claaßen J,
    7. et al.

    (2014) Consensus paper: management of degenerative cerebellar disorders. Cerebellum 13, 248–268.